{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:50Z","timestamp":1761986570048,"version":"3.40.5"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>As the COVID\u201019 vaccination campaign progresses worldwide, Guillain\u2013Barr\u00e9 syndrome (GBS) vaccine\u2010related cases have been reported. We carried out a retrospective, descriptive study of GBS patients following COVID\u201019 vaccine, submitted to the National Pharmacovigilance Center of Tunis during the period between March 2021 and May 2022. Our study aimed to identify epidemiological and clinical features of COVID\u201019 vaccine\u2010associated GBS. We found 9 cases of GBS post COVID\u201019 vaccination; 5 of them were excluded due to the lack of information, whereas 4 cases were included in this study. Men represented 75% (3\/4) of the cases. The most frequently reported vaccine type was ChAdOx1 nCoV\u201019 vaccine (<jats:italic>n<\/jats:italic>\u00a0=\u20092 reports [50%]), Ad26.COV2.S vaccine and BNT162b2 vaccine in 1. The mean time interval from vaccination to symptom onset was 15.3\u2009days. Clinical manifestations were different: classical GBS in two cases and GBS with unilateral facial palsy in the other 2 cases. All patients were treated with a course of intravenous immunoglobulin for 5\u2009days. Three patients reported clinical improvement while one case (25%) showed treatment\u2010related fluctuations. Our observations suggest that COVID\u201019 vaccines may be associated with GBS. Continuous surveillance and further studies are warranted to assess the significance of the association.<\/jats:p>","DOI":"10.1111\/bcp.15601","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:55:15Z","timestamp":1668761715000},"page":"574-578","source":"Crossref","is-referenced-by-count":7,"title":["Guillain\u2010Barr\u00e9 syndrome after COVID\u201019 vaccines: A Tunisian case series"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-2274","authenticated-orcid":false,"given":"Khouloud","family":"Berrim","sequence":"first","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghozlane","family":"Lakhoua","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Zaiem","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ons","family":"Charfi","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imen","family":"Aouinti","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarrah","family":"Kastalli","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Daghfous","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"El Aidli","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Center  Tunis 1006 Tunisia"},{"name":"Research Unit: UR17ES12, La Rabta, Faculty of Medicine University of Tunis\u2010El\u2010Manar  Tunis 1007 Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001556\u20107"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010021\u201000441\u20107"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2712.211634"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010019\u20100250\u20109"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27159"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010020\u201010124\u2010x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007719"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244527"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.820723"},{"key":"e_1_2_11_13_1","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","volume":"9","author":"Hughes RA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_14_1","first-page":"CD001798","article-title":"Plasma exchange for Guillain\u2013Barr\u00e9 syndrome","volume":"2","author":"Chevret S","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102016\u2010314862"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T08:45:25Z","timestamp":1692521125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/bcp.15601"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15601","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}